| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 07/18/2002 | WO2002055560A2 Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c |
| 07/18/2002 | WO2002055541A2 Peptides having inhibiting activity on the production of nitric oxide |
| 07/18/2002 | WO2002055531A1 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy |
| 07/18/2002 | WO2002055522A2 Novel multi-ring organic compounds for regulating gut motility and food intake |
| 07/18/2002 | WO2002055514A2 Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators |
| 07/18/2002 | WO2002055510A1 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof |
| 07/18/2002 | WO2002055501A2 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them |
| 07/18/2002 | WO2002055496A1 Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| 07/18/2002 | WO2002055495A1 Aryl piperidine derivatives as inducers of ldl-receptor expression |
| 07/18/2002 | WO2002055492A2 An improved process for preparing pure ondansetron hydrochloride dihydrate |
| 07/18/2002 | WO2002055491A2 1,2-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLORPROTEASES AND TNF-$g(a) |
| 07/18/2002 | WO2002055481A1 Prodrugs of excitatory amino acids |
| 07/18/2002 | WO2002055108A1 Targeted modification of intracellular compounds |
| 07/18/2002 | WO2002055092A1 Preventives and/or remedies for digestive diseases |
| 07/18/2002 | WO2002055090A1 Preventives for microbial infections |
| 07/18/2002 | WO2002055087A1 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain |
| 07/18/2002 | WO2002055077A1 Use of imidazolyl cyclic acetal derivatives in the manufacture of a medicament for the treatment of diseases mediated by the alk5 receptors |
| 07/18/2002 | WO2002055070A1 Dihydrofuran cyclic tanshintones used in treating hyperammonemia and hepatic encephalopathy |
| 07/18/2002 | WO2002055067A2 Fumaric acid derivatives as nf-kappab inhibitors |
| 07/18/2002 | WO2002055066A1 Fumaric acid derivatives as nf-kappa-b inhibitors |
| 07/18/2002 | WO2002055065A2 Use of an ltb4 antagonist for the treatment and/or prevention of diseases caused by increased expression of mucin genes |
| 07/18/2002 | WO2002055063A2 Fumaric acid amides |
| 07/18/2002 | WO2002055025A2 Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection |
| 07/18/2002 | WO2002055016A2 INHIBITION OF NF-λB BY TRITERPENE COMPOSITIONS |
| 07/18/2002 | WO2002055013A2 Therapeutic chromone compounds |
| 07/18/2002 | WO2002041834A3 Atorvastatin hemi-calcium form vii |
| 07/18/2002 | WO2002039978A8 Supplement to be enterally administered for parenteral nutrition or partial enteral/oral nutrition of the critically ill, the chronically ill and people with malnutrition |
| 07/18/2002 | WO2002036552A8 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |
| 07/18/2002 | WO2002034699A3 Mammalian metabolites of a tachykinin receptor antagonist |
| 07/18/2002 | WO2002029088A3 Highly expressible genes |
| 07/18/2002 | WO2002022558A3 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 07/18/2002 | WO2002019978A3 Use of ectoine or ectoine derivatives for oral care |
| 07/18/2002 | WO2002012249A3 Substituted pyrrole compounds and their use as spla2 inhibitors |
| 07/18/2002 | WO2002011704A3 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
| 07/18/2002 | WO2002006316A3 Alpha-msh related compounds and methods of use |
| 07/18/2002 | WO2002006242A3 5-substituted 2-aryl-4-pyrimidinones |
| 07/18/2002 | WO2002003989A3 Use of substituted indole compounds for treating sphincter incontinence |
| 07/18/2002 | WO2002002633A3 Transporters and ion channels |
| 07/18/2002 | WO2002002556A3 AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS α4 INTEGRIN ANTAGONISTS |
| 07/18/2002 | WO2001094391A3 Intracellular signaling proteins |
| 07/18/2002 | WO2001094345A3 Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione |
| 07/18/2002 | WO2001090103A3 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators |
| 07/18/2002 | WO2001085790A3 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 07/18/2002 | WO2001081590A3 Protein phosphatases |
| 07/18/2002 | WO2001079468A3 Drug metabolizing enzymes |
| 07/18/2002 | WO2001079282A3 Molecules associated with human reproduction |
| 07/18/2002 | WO2001072822A3 Genes involved in intestinal inflammatory diseases and use thereof |
| 07/18/2002 | WO2001072728A3 Novel piperazine derivatives |
| 07/18/2002 | WO2001066747A3 Proteins named fctrx and nucleic acids encoding same |
| 07/18/2002 | WO2001056547A3 Preparation of aqueous clear solution dosage forms with bile acids |
| 07/18/2002 | WO2001045679A3 Use of chemotherapeutic agents for topical treatment |
| 07/18/2002 | WO2001005834A9 Human tumor necrosis factor receptors tr13 and tr14 |
| 07/18/2002 | WO2000078972A9 Regulation with binding cassette transporter protein abc1 |
| 07/18/2002 | US20020095024 B7-related nucleic acids and polypeptides useful for immunomodulation |
| 07/18/2002 | US20020095002 Process for removing bile salts from a patient and alkylated compositions thereor |
| 07/18/2002 | US20020094987 Amide or thioamide substituted benzimidazole or quinoxaline derivatives; therapeutic utility via inhibition of tumor necrosis factor or phosphodiesterase |
| 07/18/2002 | US20020094980 Preparing 1,1-dioxo-2-phenyl-3-carboxy-4-phenyl-1,2-benzo(e)-thiazines by a five-step process starting with a (2-(methyl-oxycarbonyl-)phenyl-sulfonamido-)benzene; alkylation; cyclization; hydroxylation; esterification and coupling |
| 07/18/2002 | US20020094960 Specifically unipolar depression, treatment-refractory depression, resistant depression, anxious depression and dysthymia; 2-sulfamatomethyltetrahydropyrans and sulfamato-methylcyclohexanes, e.g. topiramate |
| 07/18/2002 | US20020094955 Plasminogen-like polynucleotides, polypeptides, and antibodies |
| 07/18/2002 | US20020094328 Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions |
| 07/18/2002 | DE10064312A1 Cholinpyruvat, Verfahren zu dessen Herstellung, Cholinpyruvat enthaltende Formulierung sowie deren Verwendung Choline pyruvate, containing process for the production thereof, choline pyruvate formulation and the use thereof |
| 07/18/2002 | CA2776023A1 Fumaric acid amides |
| 07/18/2002 | CA2436876A1 Transcriptional mediators of blood vessel development and endothelial differentiation |
| 07/18/2002 | CA2434573A1 Agent for protection against microorganism infection |
| 07/18/2002 | CA2434274A1 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them |
| 07/18/2002 | CA2434044A1 1,2-disubstituted cyclic inhibitors of matrix metallorproteases and tnf-alpha |
| 07/18/2002 | CA2433950A1 Therapeutic chromone compounds |
| 07/18/2002 | CA2433720A1 An improved process for preparing pure ondansetron hydrochloride dihydrate |
| 07/18/2002 | CA2433451A1 Use of an ltb4 antagonist for the treatment and/or prevention of diseases caused by increased expression of mucin genes |
| 07/18/2002 | CA2433070A1 Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection |
| 07/18/2002 | CA2433066A1 Novel multi-ring organic compounds for regulating gut motility and food intake |
| 07/18/2002 | CA2432341A1 Method for inhibiting the expression of a target gene and medicament for treating a tumor disease |
| 07/18/2002 | CA2429946A1 Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c |
| 07/18/2002 | CA2429177A1 Inhibition of nf-.kappa.b by triterpene compositions |
| 07/18/2002 | CA2428497A1 Targeted modification of intracellular compounds |
| 07/18/2002 | CA2428075A1 Fumaric acid derivatives as nf-kappab inhibitors |
| 07/17/2002 | EP1222683A1 Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
| 07/17/2002 | EP1222463A2 Allosteric sites on muscarinic receptors |
| 07/17/2002 | EP1222275A2 Serum amyloid a isoform from colostrum |
| 07/17/2002 | EP1222255A1 Polypeptide fragments comprising c-terminal portion of helicobacter catalase |
| 07/17/2002 | EP1222253A1 Retinoid receptor interacting polynucleotides, polypeptides, and antibodies |
| 07/17/2002 | EP1222209A2 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 07/17/2002 | EP1222200A1 Vaccine |
| 07/17/2002 | EP1222193A2 Imidazole derivatives as phosphodiesterase vii inhibitors |
| 07/17/2002 | EP1222188A1 Novel imidazopyridine carbonitrile compounds |
| 07/17/2002 | EP1222187A2 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 07/17/2002 | EP1222171A1 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 07/17/2002 | EP1222170A1 Novel nicotinonitrile compounds |
| 07/17/2002 | EP1222169A1 Novel trisubstituted pyridine compounds |
| 07/17/2002 | EP1222162A1 Novel ltb 4? antagonist, method for the production thereof and its use as a medicament |
| 07/17/2002 | EP1221965A1 Use of tgf beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa |
| 07/17/2002 | EP1221963A1 Methods of inhibiting osteoclastogenesis |
| 07/17/2002 | EP1221962A2 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 07/17/2002 | EP1221955A2 Immunostimulatory nucleic acids |
| 07/17/2002 | EP1221951A1 Treatment of pancreatic disease |
| 07/17/2002 | EP1221947A2 Soft gel capsule resistant to gastric juices |
| 07/17/2002 | EP1221941A1 Powder pharmaceutical formulations |
| 07/17/2002 | EP1221939A1 Ortho ester lipids |
| 07/17/2002 | EP1221908A1 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| 07/17/2002 | EP1105002B1 Carbohydrates mixture |